Cases
CoLucid Pharmaceuticals, Inc. (NASDAQ : CLCD)
Merger
Overview
Overview
- Date:
- 2/9/2017
- Company Name:
- CoLucid Pharmaceuticals, Inc.
- Stock Symbol:
- CLCD
- Company Name - Buyer:
- Eli Lilly and Company
- Class Period:
- FROM 2/3/2017
- Status:
- Closed/Complete
- Merger Announcement Date:
- 1/18/2017
- Court:
- U.S. District Court: Massachusetts
NEW YORK, February 9, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who held CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) securities on February 3, 2017 (the “Class Period”).
On January 18, 2017, the two parties announced the signing of a definitive merger agreement pursuant to which Eli Lilly and Company will acquire CoLucid Pharmaceuticals, Inc.. As a result of the merger, Neustar shareholders are only anticipated to receive $46.50 in cash for each share of CoLucid common stock.
The complaint alleges that the company failed to conduct a fair sales process and failed to disclose all material information regarding the sale of the company.
If you held CoLucid securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On January 18, 2017, the two parties announced the signing of a definitive merger agreement pursuant to which Eli Lilly and Company will acquire CoLucid Pharmaceuticals, Inc.. As a result of the merger, Neustar shareholders are only anticipated to receive $46.50 in cash for each share of CoLucid common stock.
The complaint alleges that the company failed to conduct a fair sales process and failed to disclose all material information regarding the sale of the company.
If you held CoLucid securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.